Sharfstein: US FDA Incentives Not Broke, But Fix Them
Executive SummaryThe former US FDA principal deputy commissioner argues that accelerated approval, fast track and breakthrough designation standards may need updating, along with orphan and pediatric exclusivity requirements, to enhance the programs' efficacy.
You may also be interested in...
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
Pink Sheet infographic illustrates new drug approval trends and highlights from the past decade at the US FDA.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.